



UNIVERSITY OF LEEDS

This is a repository copy of *Aztreonam lysine inhalation solution stabilises lung function decline in patients with cystic fibrosis and moderate to severe lung disease*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/137147/>

Version: Accepted Version

---

**Proceedings Paper:**

Chadwick, HK [orcid.org/0000-0002-8022-5490](https://orcid.org/0000-0002-8022-5490), White, H, Shaw, N et al. (5 more authors) (2018) Aztreonam lysine inhalation solution stabilises lung function decline in patients with cystic fibrosis and moderate to severe lung disease. In: *Pediatric Pulmonology*. NACFC 2018: the 32nd Annual North American Cystic Fibrosis Conference, 18-20 Oct 2018, Denver, CO, USA. Wiley , p. 331.

<https://doi.org/10.1002/ppul.24152>

---

© 2018 Wiley Periodicals, Inc. This is the peer reviewed version of the following article: Chadwick, HK , White, H, Shaw, N et al. (5 more authors) (2018) Aztreonam lysine inhalation solution stabilises lung function decline in patients with cystic fibrosis and moderate to severe lung disease. In: (2018), *Poster Session Abstracts*. *Pediatr Pulmonol*, 53: S148-S456, which has been published in final form at <https://doi.org/10.1002/ppul.24152>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance with the publisher's self-archiving policy.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

# AZTREONAM LYSINE INHALATION SOLUTION (AZLI, CAYSTON®, GILEAD) STABILISES LUNG FUNCTION DECLINE IN PATIENTS WITH CYSTIC FIBROSIS AND MODERATE TO SEVERE LUNG DISEASE

## AUTHORS:

Chadwick, Helen K<sup>1,2</sup>; White, Helen<sup>1,2,3</sup>; Shaw, Nicola<sup>2</sup>; Etherington, Christine<sup>2</sup>; Clifton, Ian<sup>2</sup>; Pollard, Kim<sup>2</sup>; Whitaker, Paul<sup>2</sup>; Peckham, Daniel<sup>1,2</sup>

## INSTITUTIONS:

<sup>1</sup> Respiratory Medicine, Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK

<sup>2</sup> Adult Cystic Fibrosis Unit, Leeds Teaching Hospitals Trust, Leeds, UK

<sup>3</sup> Nutrition & Dietetic Group, Leeds Beckett University, Leeds, UK

## ABSTRACT BODY:

**Introduction:** *P. aeruginosa* (PA) is the most common pathogen and is associated with worse lung function, nutrition and increased mortality. Aztreonam lysine inhalation solution (AZLI, Cayston®, Gilead) is licenced for use in patients with CF aged six years and older, with chronic PA (CPA). The aim of this audit was to assess the usage and clinical outcome of AZLI in a large adult CF unit.

**Methods:** Data was extracted between 2011 and 2017. A total of 168 patients received at least one dose of AZLI. Indications included CPA, PA eradication and combination therapy in acute exacerbations. Patients who received at least 50% of doses (91/168 patients) were included with 15 subjects being excluded due to pregnancy, lung transplant and recent treatment. Data was extracted for age, weight, BMI, lung function, CRP, plasma viscosity (PV), white cell count (WCC), and days of IVs .

**Results:** A total of 76 patients met inclusion criteria; PA (n=62) and Burkholderia Cepacia Complex (BCC) +/- PA (n=14). Of these 76 patients, 3 died within 1 year of prescription of AZLI, 4 died within 2 years, and 6 died within 3 years. Prior to the initiation of AZLI, the majority of patients had failed to respond to alternative inhaled antipseudomonal treatment; promixin monotherapy (PA n=17; BCC/PA n=2), tobramycin monotherapy (PA n=28; BCC/PA n=8), or a combination of the 2 treatments (PA n= 14; BCC/PA n=2). AZLI was prescribed on an alternate month basis with another agent in 49 PA (20 promixin, 29 tobramycin) and 8 BCC patients (3 promixin, 5 tobramycin). There were no differences in clinical characteristics at baseline between PA and BCC patients except for weight where BCC patients were heavier. AZLI therapy was initiated in patients with low FEV1. In both groups there was a significant decline in FEV1 prior to initiating therapy (p<0.001) which subsequently stabilised (NS). There was a significant increase in CRP and PV in patients with PA over the study period (Table).

**Conclusion:** AZLI therapy stabilises lung function decline in patients with PA even with moderate and severe disease. Data suggests that AZLI was being prescribed late in the disease course and should be considered sooner. Further work to assess adherence to therapy is needed.

*Supported by Gilead Sciences UK & Ireland Ltd.*

Table: Within and between group effects (PA v BCC) from 1 year pre-AZLI to 1 year post

Patient characteristic		1 year pre-AZLI	Baseline	1 year post AZLI	Within Group effect	Between Group effect
Weight (Kg)	PA	62.7(±11.9)	62.9(±12.0)	62.8(±12.2)	p = 0.88 p = 0.82	p = 0.62
	BCC	68.8(±12.6)	68.1(±13.1)	68.5(±13.7)		
BMI (Kg/m <sup>2</sup> )	PA	22.0(±3.0)	22.1(±3.1)	22.1(±3.1)	p = 0.42 p = 0.83	p = 0.58
	BCC	23.6(±3.0)	23.4(±3.1)	23.5(±3.1)		
FEV <sub>1</sub> (%)	PA	46.2(±14.7)	42.6(±14.2)	40.7(±14.8)	p < 0.001 p = 0.008	p = 0.82
	BCC	50.4(±15.1)	46.8(±15.5)	43.9(±15.1)		
FVC (%)	PA	66.1(±17.4)	62.8(±16.3)	60.6(±18.6)	p < 0.001 p = 0.02	p = 0.62
	BCC	72.5(±16.3)	68.5(±17.8)	65.4(±18.3)		
CRP	PA	16.6(±10.6)	22.4(±17.9)	24.5(±20.0)	p = 0.005 p = 0.23	p = 0.17
	BCC	19.8(±17.2)	15.4(±9.4)	25.9(±26.4)		
PV	PA	1.8(±0.13)	1.83(±0.17)	1.85(±0.19)	p = 0.004 p = 0.89	p = 0.37
	BCC	1.83(±0.11)	1.84(±0.08)	1.85(±0.11)		
WCC	PA	6.7(±2.2)	6.8(±2.1)	7.1(±2.5)	p = 0.08 p = 0.79	p = 0.73
	BCC	7.7(±2.8)	7.6(±2.3)	7.9(±3.0)		
Days of IVs	PA	13.9(±7.0)	15.5(±7.6)	17.1(±13.2)	p = 0.09 p = 0.36	p = 0.07
	BCC	6.8(±11.5)	20.3(±21.4)	14.1(±7.7)		